Bank of Montreal
ZNTL icon

Bank of Montreal’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bank of Montreal’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,459
Closed -$37.3K – 3786
2025
Q1 		$37.3K Buy
+23,459
New +$50.6K ﹤0.01% 3117
2024
Q3 		– Sell
-98,331
Closed -$1.13M – 4303
2024
Q2 		$1.13M Buy
+98,331
New +$1.1M ﹤0.01% 1965
2022
Q1 		– Sell
-3,604
Closed -$304K – 4308
2021
Q4 		$304K Buy
3,604
+115
+3% +$8.9K ﹤0.01% 2717
2021
Q3 		$219K Buy
+3,489
New +$201K ﹤0.01% 3291
2021
Q2 		– Sell
-4,225
Closed -$179K – 4997
2021
Q1 		$179K Sell
4,225
-3,346
-44% -$144K ﹤0.01% 3162
2020
Q4 		$367K Buy
7,571
+3,937
+108% +$178K ﹤0.01% 2876
2020
Q3 		$124K Buy
3,634
+2,707
+292% +$94.8K ﹤0.01% 2976
2020
Q2 		$38K Buy
+927
New +$35.6K ﹤0.01% 3562

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Bank of Montreal's ZNTL Position: Q2 2025 in Review

Bank of Montreal sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 23,459 shares — an estimated $37.3K sold.

Bank of Montreal first reported a position in ZNTL in Q2 2020 and held it in 8 quarters. The position peaked at $1.13M in Q2 2024. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Bank of Montreal reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bank of Montreal sold 23,459 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $37.3K.
  • Bank of Montreal first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 8 quarters.
  • Bank of Montreal's Zentalis Pharmaceuticals position peaked at $1.13M in Q2 2024.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Bank of Montreal's 13F filing for Q2 2025, filed 5 Aug 2025.